



ACN 010 126 708

ASX Release
22 May 2018

Results of RHS Scheme Meeting

Adelaide, 22 May 2018: RHS Limited (ASX: RHS) (“RHS” or “the **Company**”) is pleased to announce that its shareholders have voted to approve the scheme of arrangement (**Scheme**) under which it is proposed that PerkinElmer Holdings Pty Ltd, being a wholly owned subsidiary of PerkinElmer, Inc., will acquire all of the issued shares in RHS.

The votes were cast at the Scheme Meeting held today at the TechInSA Conference Centre, TechInSA Incubator, 40-46 West Thebarton Road, Thebarton SA.

Information in relation to the resolution passed by shareholders of RHS at the Scheme Meeting is set out in the Annexure to this release. The resolution was passed by majorities comfortably exceeding the required majorities, specifically:

- 97.13% of RHS shareholders present and voting at the Scheme Meeting (whether in person or by proxy, attorney or corporate representative) voted in favour of the resolution to approve the Scheme; and
- 99.97% of the votes cast at the Scheme meeting (whether in person or by proxy, attorney or corporate representative) were in favour of the resolution to approve the Scheme.

RHS’s application to the Federal Court of Australia for approval of the Scheme will be held at the Second Court Hearing scheduled for Tuesday, 29 May 2018 at 3.00pm (Adelaide time). If that approval is granted, the Scheme is scheduled to be implemented on Thursday, 14 June 2018.

Further announcements regarding the progress of the Scheme will be made in due course.

For further information please contact:

Dr Michelle Fraser
CEO and Managing Director
Tel: (+61 8) 8152 9348
michelle.fraser@rhsc.com.au

Dr David Brookes
Chairman
Tel: (+61 8) 8152 9383
david.brookes@rhsc.com.au

About RHS

RHS is a developer of advanced single cell genomic technologies focussed on improving health and research outcomes, based on deep technical experience in the field. DOPlify® is a platform product for whole genome amplification (WGA) of single or small numbers of cells. DOPlify® is applicable to the global Next Generation Sequencing (NGS) market. PG-Seq™, RHS’ NGS workflow and EmbryoCollect®, RHS’ microarray workflow, both incorporate DOPlify® and have been specifically designed for the genetic screening of IVF embryos.

RHS Ltd.
ACN 010 126 708
ASX: RHS

Issued Capital
89.9 million shares
7.4 million options

Registered Office
Level One, TechInSA
Incubator,
40-46 West Thebarton Road,
Thebarton, SA 5031

Tel: +61 8 8152 9380
WEB www.rhsc.com.au

Directors
Dr David Brookes (Chairman)
Sue MacLeman
Johnathon Matthews
Dr Michelle Fraser (CEO)

**Finance Officer
& Company Secretary**
Raymond Ridge

ANNEXURE

SCHEME MEETING VOTING SUMMARY

In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), the following information is provided in relation to the resolution passed by the shareholders of RHS Limited at its Scheme Meeting on Tuesday, 22 May 2018.

Resolution	
<i>“That pursuant to and in accordance with section 411 of the Corporations Act, the scheme of arrangement proposed to be entered into between RHS and the RHS Shareholders, as more particularly set out in the Scheme Booklet accompanying this notice of meeting, is agreed to (with or without modification as approved by the Court).”</i>	
Summary of proxy votes:	
Total number of proxy votes exercisable by all proxies validly appointed	73,051,357
Total number of proxy votes in respect of which the appointments specified that:	
• the proxy is to vote for the resolution	70,565,157
• the proxy is to vote against the resolution	25,316
• the proxy is to abstain on the resolution	-
• the proxy may vote at the proxy's discretion	2,460,884
The resolution was carried on a poll, details of which are below.	
Total number of votes cast on the poll:	
• in favour of the resolution	73,033,448
• against the resolution	25,316
• abstaining on the resolution	-